ReviewFrontiers in pediatrics2022
New Insights on Juvenile Psoriatic Arthritis.
Review in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis.Clinical rheumatology · 2025Guideline
- Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data.Paediatric drugs · 2026Trial
- Differential transcriptional and epigenetic signatures in CD4Journal of translational autoimmunity · 2026Article
- Pictorial insights into high-resolution ultrasound for various subtypes of juvenile idiopathic arthritis.Journal of ultrasound · 2026Review
- A Narrative Review of Secukinumab in Spondyloarthritis and Psoriatic Arthritis: Treating the Whole Patient.Rheumatology and therapy · 2026Review
- Development of Arthritis in a Large Real-World Cohort of Patients With Pediatric Onset Psoriasis.Journal of psoriasis and psoriatic arthritis · 2026Article
- Pharmacokinetics and Safety of Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Results of the Real-World Ustekinumab Pediatric Opportunistic Pharmacokinetics Study (U-POPS).Rheumatology and therapy · 2026Article
- Case Report: Early-onset juvenile psoriatic arthritis presenting at 15 months-a diagnostic challenge in infancy.Frontiers in pediatrics · 2026Article
- Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Juvenile Idiopathic Arthritis-The Rubik's Cube of Pediatric Rheumatology.Children (Basel, Switzerland) · 2025Article
- Clinical and Demographic Characteristics of Dermatoses with Bimodal Distribution Pattern: A Concise Review.Indian dermatology online journal · 2025Article
- The Challenges of New Biologic Therapies in Pediatrics: An Update on the Limited Therapeutic Options for Juvenile Psoriatic Arthritis.Rheumatic diseases clinics of North America · 2025Review
- Characteristics That Predict Psoriatic Arthritis by the Classification Criteria for Psoriatic Arthritis in Patients With Juvenile Idiopathic Arthritis 18 Years After Disease Onset.ACR open rheumatology · 2025Article
- A Rare Case of Juvenile Psoriatic Arthritis.Cureus · 2024Article
- Systemic Therapy of Psoriasis in Children-Proposal of an Algorithm for Interdisciplinary Teamwork.Journal of clinical medicine · 2024Article
- The impact of psoriasis on wellbeing and clinical outcomes in juvenile psoriatic arthritis.Rheumatology (Oxford, England) · 2024Article
- Existing and Emerging Targeted Therapies in Juvenile Psoriatic Arthritis: Challenges and Unmet Needs.Paediatric drugs · 2024Review
- Integrative analysis reveals novel insights into juvenile idiopathic arthritis pathogenesis and shared molecular pathways with associated traits.Frontiers in genetics · 2024Article
- Pediatric Psoriasis with or without Arthritis: Does It Make a Difference?Journal of clinical medicine · 2023Article
- MRI Findings in Axial Psoriatic Spondylarthritis.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile psoriatic arthritis (JPsA) is a relatively rare condition in childhood as it represents approximately 5% of the whole Juvenile Idiopathic Arthritis (JIA) population. According to International League of Associations of Rheumatology (ILAR) classification, JPsA is defined by the association of arthritis and psoriasis or, in the absence of typical psoriatic lesions, with at least two of the following: dactylitis, nail pitting, onycholysis or family history of psoriasis in a first-degree relative. However, recent studies have shown that this classification system could conceal more homogeneous subgroups of patients differing by age of onset, clinical characteristics and prognosis. Little is known about genetic factors and pathogenetic mechanisms which distinguish JPsA from other JIA subtypes or from isolated psoriasis without joint involvement, especially in the pediatric population. Specific clinical trials testing the efficacy of biological agents are lacking for JPsA, while in recent years novel therapeutic agents are emerging in adults. In this review, we summarize the clinical features and the current evidence on pathogenesis and therapeutic options for JPsA in order to provide a comprehensive overview on the clinical management of this complex and overlapping entity in childhood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.